98%
921
2 minutes
20
Objective: To investigate the effect and possible mechanism of up-regulation of p-Akt by doxycycline (DOX) on myeloma cell line H929.
Methods: Multiple myeloma cell line H929 was treated with DOX at different concentrations for different times, and cell proliferation rate was measured by CCK-8 assay. The protein expression level of p-Akt, PTEN, p-PDK1, p-mTOR, p-GSK-3β, and p-BAD was analyzed by Western blot. The mRNA levels of mTOR, BCL-2, and NF-κB was analyzed by RT-PCR. PI3K inhibitor Wortmannin was used to antagonize the up-regulation of p-Akt, and the cell proliferation and p-Akt protein expression level were analyzed by CCK-8 assay and Western blot respectively.
Results: DOX could inhibit the proliferation of H929 cells and up-regulate the expression of p-Akt at the same time. The protein levels of both p-PDK1 and PTEN in H929 cells did not alter significantly during DOX treatment. The expressions of p-BAD and p-GSK-3β were up-regulated in H929 cells after treated with DOX, but the expression of p-mTOR was not altered. The mRNA levels of mTOR, BCL-2, and NF-κB in H929 were all down-regulated in H929 cells during DOX treatment. The effect up-regulating p-Akt level by DOX was suppressed when DOX combined with PI3K inhibitor Wortmannin and Wortmannin could enhance the inhibitory effect of DOX in H929 cells.
Conclusion: DOX can activate PI3K/Akt signaling pathway in H929 cells, and antagonizing this effect of DOX may enhance its cytotoxicity to myeloma cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.05.029 | DOI Listing |
Oncol Lett
September 2025
Department of Clinical Laboratory, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nangchang, Jiangxi 330000, P.R. China.
Multiple myeloma (MM) is a malignant tumor that originates in the plasma cells of the bone marrow, interfering with the production of healthy blood cells and causing notable damage to bones and other tissues. Currently, the treatment options for MM are limited and often fail to provide effective and well-tolerated solutions. Silymarin, a primary active compound found in the dried fruit of , is known for its inhibitory action on lipoxygenases and peroxidases.
View Article and Find Full Text PDFSci Rep
July 2025
Phase I Clinical Experimental Research Center, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, PR China.
This study aims to explore the pharmacological mechanism of Brucea javanica (BJ) in treating multiple myeloma (MM) through network pharmacology and validate this mechanism via in vitro experiments. Active pharmaceutical ingredients (APIs) of BJ and their potential targets were identified, along with MM-related targets. By plotting protein-protein interaction (PPI) networks, hub genes responsible for BJ in treating MM were identified and subjected to molecular docking.
View Article and Find Full Text PDFJ Med Chem
July 2025
Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
B-cell maturation antigen (BCMA) is a clinically validated biomarker and therapeutic target in multiple myeloma (MM). Here, we report the design, synthesis, and preclinical evaluation of an immunoPET probe, [Zr]Zr-DFO-PFBH0L0, derived from a novel humanized anti-BCMA monoclonal antibody. The antibody was conjugated with deferoxamine (DFO) and radiolabeled with zirconium-89 (Zr), yielding a probe with excellent in vitro stability.
View Article and Find Full Text PDFRSC Med Chem
May 2025
State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences Shanghai 201203 China.
Thyroid hormone receptor-interacting protein-13 (TRIP13) is an AAA ATPase that regulates protein complex assembly and disassembly and is known to be a chromosomal instability gene with the ability to repair DNA double-strand breaks. TRIP13 overexpression has been linked to the proliferation and development of many human malignancies, including multiple myeloma (MM). Accordingly, TRIP13 is recognized as a potential drug target for anticancer drug development.
View Article and Find Full Text PDFActa Pharmacol Sin
September 2025
Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Selective nuclear export inhibitor selinexor (SEL) represents a promising therapeutic strategy for relapsed/refractory multiple myeloma (RRMM). But its mechanisms of action as well as factors that influence therapeutic responses have not been fully characterized yet. In this study we employed catTFRE proteomics technique to profile changes in nuclear abundance of activated transcription factors (TFs)/co-factors (TCs) in myeloma cells following SEL treatment.
View Article and Find Full Text PDF